Anesthesia in Patients With Mitochondrial Disease

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against GLRA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

• 2025-08-12Phase 3 first posted: Xijing Hospital, Desflurane group + Propofol group (NCT07116733)
• 2025-08-01Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Inahled Isoflurane + Propofol, midazolam (NCT07099014)
• 2025-07-28Results posted on the registry: University of Texas Southwestern Medical Center, Rocuronium + Sugammadex (NCT06225466)
• 2025-07-20Results posted on the registry: West Virginia University, Sugammadex + neostigmine (NCT03111121)
• 2025-06-08Phase 3 first posted: Hany Mohammed El-Hadi Shoukat Mohammed, Group (E): receive aminophylline early intraoperatively, + Group (L) received aminophylline late intraoperatively (NCT07011134)
• 2025-05-30Phase 3 first posted: Dr. Asma Abdus Salam, Nalbuphine Injection + Next Generation Sequencing (NCT06996561)
• 2025-05-28Results posted on the registry: Pelita Harapan University, Dexmedetomidine + Sevoflurane (NCT06482125)
• 2025-05-25Results posted on the registry: Sedana Medical, Midazolam + Isoflurane (NCT04684238)
• 2025-03-24Results posted on the registry: Emory University, Standard of Care Anesthesia (NCT03408340)
• 2025-03-24Also stopped (terminated): Emory University, Standard of Care Anesthesia (NCT03408340)
• 2025-03-21Phase 3 first posted: Cairo University, Gabapentin 600 mg capsules + Gabapentin 400 mg capsules (NCT06887998)
• 2025-03-14Also stopped (terminated): Peter MacCallum Cancer Centre, Australia, Sevoflurane + Propofol (NCT04316013)
• 2025-03-13Phase 3 first posted: Ain Shams University, conventional analgesic regimen (NCT06873906)
• 2025-03-11Results posted on the registry: Erasmus Medical Center, a drug against GLRA1 (NCT05525104)
• 2025-02-17Phase 3 first posted: Ain Shams University, we will give the patient 0.1 mg nalbuphine 15 min before the end of the procedure + we will give the patient 0.5 mg dexmedetomidine 15 min before the end of the procedure (NCT06830564)
• 2025-02-05Phase 3 first posted: Sedana Medical, Inhaled isoflurane administered by Sedaconda ACD-S + Intravenous infusion of propofol (NCT06809218)
• 2025-02-05Also stopped (withdrawn): Kocaeli City Hospital, Sevoflurane Group + Desflurane Group (NCT06457958)
• 2025-01-03Also stopped (withdrawn): University of Iowa, Propofol + Dexmedetomidine (NCT06756971)
• 2025-01-03Phase 3 first posted: University of Iowa, Propofol + Dexmedetomidine (NCT06756971)
• 2024-12-18Phase 3 first posted: Sahiwal medical college sahiwal, inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h + inj. lignocaine infusion @1-2 mg/kg/h (NCT06740903)
• 2024-11-20Results posted on the registry: Christine Oryhan, Opioid Anesthetics + Non Opioid Analgesics (NCT04081545)
• 2024-10-03Phase 3 first posted: Mayo Clinic, Sevoflurane + Isoflurane (NCT06624592)
• 2024-09-19Results posted on the registry: Emory University, Ketorolac + Standard of Care (NCT03467750)
• 2024-09-05Results posted on the registry: The University of Texas Health Science Center, Houston, Sedation + General Anesthesia (GA) (NCT03263117)
• 2024-08-20Results posted on the registry: Medical University of South Carolina, propofol + sevoflurane (NCT02697448)

What is not public

• Internal portfolio and board discussions
• Unpublished trial data and interim analyses
• Terms of any partner or licence decision